Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC elderly task force, lung cancer group and international society for geriatric oncology

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1270-1283

  Pallis, Athanasios G ^a   Gridelli, C ^b   Wedding, U ^c   Faivre Finn, C ^d   Veronesi, G ^e   Jaklitsch, M ^f   Luciani, A ^g   O'Brien, M ^h  

^a EORTC DATA CENTER   (Belgium)

^b S G MOSCATI HOSPITAL   (Italy)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f HARVARD MEDICAL SCHOOL   (United States)

^g SAN PAOLO HOSPITAL   (Italy)

^h The Royal Marsden NHS Foundation   (United Kingdom)

Author keywords

Age; Elderly; EORTC; NSCLC; SIOG

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADVANCED CANCER; ARTERIAL THROMBOEMBOLISM; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL OBSERVATION; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ELDERLY CARE; EVIDENCE BASED MEDICINE; GERIATRIC ASSESSMENT; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MEDICAL SOCIETY; METASTASIS; MINIMALLY INVASIVE SURGERY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIDEO ASSISTED THORACOSCOPIC SURGERY; WEIGHT REDUCTION; AGED; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS;

EID: 84903727209     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu022     Document Type: Review

References (116)

1. http://seer.cancer.gov/statfacts/html/lungb.html. (June 2013, date last accessed).
2. Sacher AG, Le LW, Leighl NB et al. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol 2013; 8: 366-368.
3. Pallis AG, Fortpied C, Wedding U et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 2010; 46: 1502-1513.
4. Pallis AG, Gridelli C, van Meerbeeck JP et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol 2010; 21: 692-706.
5. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD; http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission. posted to the SEER web site, April 2013 (June 2013, date last accessed).
6. Giroux-Leprieur E, Labrune S, Giraud V et al. Delay between the initial symptoms, the diagnosis and the onset of specific treatment in elderly patients with lung cancer. Clin Lung Cancer 2012; 13: 363-368.
7. Sterlacci W, Stockinger R, Schmid T et al. The elderly patient with surgically resected non-small cell lung cancer-a distinct situation? Exp Gerontol 2012; 47: 237-242.
8. Goodgame B, Viswanathan A, Zoole J et al. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol 2009; 4: 1370-1374.
9. Pallis AG, Scarci M. Are we treating enough elderly patients with early stage nonsmall cell lung cancer? Lung Cancer 2011; 74: 149-154.
10. Takamochi K, Oh S, Matsuoka J et al. Risk factors for morbidity after pulmonary resection for lung cancer in younger and elderly patients. Interact Cardiovasc Thorac Surg 2011; 12: 739-743.
11. Rivera C, Falcoz PE, Rami-Porta R et al. Mediastinal lymphadenectomy in elderly patients with non-small-cell lung cancer. Eur J Cardiothorac Surg 2013; 44: 88-92.
12. Tsao AS, Liu S, Lee JJ et al. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol 2012; 7: 1645-1652.
13. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with lowdose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
14. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006; 36: 216-220.
15. Walter LC, Brand RJ, Counsell SR et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA 2001; 285: 2987-2994.
16. http://globocan.iarc.fr/. (September 2013, date last accessed).
17. Jaklitsch MT, Jacobson FL, Austin JH et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012; 144: 33-38.
18. Jacobson FL, Austin JH, Field JK et al. Development of the American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of the American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg 2012; 144: 25-32.
19. NCCN guidelines Version 1.2014. Lung Cancer Screening. www.nccn.org (September 2013, date last accessed).
20. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285: 2750-2756.
21. Lewis CL, Kistler CE, Amick HR et al. Older adults' attitudes about continuing cancer screening later in life: a pilot study interviewing residents of two continuing care communities. BMC Geriatr 2006; 6: 10.
22. Torke AM, Schwartz PH, Holtz LR et al. Older adults and forgoing cancer screening: 'I think it would be strange'. JAMA Intern Med 2013; 173: 526-531.
23. Veronesi G, Maisonneuve P, Bellomi M et al. Estimating overdiagnosis in lowdose computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2012; 157: 776-784.
24. Fanucchi O, Ambrogi MC, Dini P et al. Surgical treatment of non-small cell lung cancer in octogenarians. Interact Cardiovasc Thorac Surg 2011; 12: 749-753.
25. Rivera C, Dahan M, Bernard A et al. Surgical treatment of lung cancer in the octogenarians: results of a nationwide audit. Eur J Cardiothorac Surg 2011; 39: 981-986.
26. Rivera C, Falcoz PE, Bernard A et al. Surgical management and outcomes of elderly patients with early stage non-small cell lung cancer: a nested casecontrol study. Chest 2011; 140: 874-880.
27. Blanchard EM, Arnaoutakis K, Hesketh PJ. Lung cancer in octogenarians. J Thorac Oncol 2010; 5: 909-916.
28. Wang S, Wong ML, Hamilton N et al. Impact of age and comorbidity on nonsmall- cell lung cancer treatment in older veterans. J Clin Oncol 2012; 30: 1447-1455.
29. Palma DA, Tyldesley S, Sheehan F et al. Stage I non-small cell lung cancer (NSCLC) in patients aged 75 years and older: does age determine survival after radical treatment? J Thorac Oncol 2010; 5: 818-824.
30. van der Drift MA, Karim-Kos HE, Siesling S et al. Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J Thorac Oncol 2012; 7: 291-298.
31. Haasbeek CJ, Palma D, Visser O et al. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012; 23: 2743-2747.
32. Gray SW, Landrum MB, Lamont EB et al. Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer. Cancer 2012; 118: 1404-1411.
33. Chambers A, Routledge T, Pilling J et al. In elderly patients with lung cancer is resection justified in terms of morbidity, mortality and residual quality of life? Interact Cardiovasc Thorac Surg 2010; 10: 1015-1021.
34. Rueth NM, Parsons HM, Habermann EB et al. Surgical treatment of lung cancer: predicting postoperative morbidity in the elderly population. J Thorac Cardiovasc Surg 2012; 143: 1314-1323.
35. Ginsberg RJ, Hill LD, Eagan RT et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 1983; 86: 654-658.
36. Allen MS, Darling GE, Pechet TT et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006; 81: 1013-1019.
37. McKenna RJ, Jr, Houck W, Fuller CB. Video-assisted thoracic surgery lobectomy: experience with 1,100 cases. Ann Thorac Surg 2006; 81: 421-425.
38. Onaitis MW, Petersen RP, Balderson SS et al. Thoracoscopic lobectomy is a safe and versatile procedure: experience with 500 consecutive patients. Ann Surg 2006; 244: 420-425.
39. Billmeier SE, Ayanian JZ, He Y et al. Predictors of nursing home admission, severe functional impairment, or death one year after surgery for non-small cell lung cancer. Ann Surg 2013; 257: 555-563.
40. Chang MY, Mentzer SJ, Colson YL et al. Factors predicting poor survival after resection of stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 134: 850-856.
41. Wong DR, Henteleff HJ. Ten-year follow-up of a province-wide cohort of surgical lung cancer patients in Nova Scotia. Can J Surg 2008; 51: 257-262.
42. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-622.
43. Bolukbas S, Eberlein MH, Schirren J. Pneumonectomy vs. sleeve resection for non-small cell lung carcinoma in the elderly: analysis of short-term and longterm results. Thorac Cardiovasc Surg 2011; 59: 142-147.
44. Okami J, Ito Y, Higashiyama M et al. Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. Ann Thorac Surg 2010; 90: 1651-1656.
45. Cheng YD, Duan CJ, Dong S et al. Clinical controlled comparison between lobectomy and segmental resection for patients over 70 years of age with clinical stage I non-small cell lung cancer. Eur J Surg Oncol 2012; 38: 1149-1155.
46. Okasaka T, Usami N, Taniguchi T et al. Can non-performance of radical systematic mediastinal lymphadenectomy be justified in elderly lung cancer patients? An evaluation using propensity-based survival analysis. Eur J Cardiothorac Surg 2010; 38: 27-33.
47. Shapiro M, Mhango G, Kates M et al. Extent of lymph node resection does not increase perioperative morbidity and mortality after surgery for stage I lung cancer in the elderly. Eur J Surg Oncol 2012; 38: 516-522.
48. Kalathiya RJ, Saha SP. Pneumonectomy for non-small cell lung cancer: outcomes analysis. South Med J 2012; 105: 350-354.
49. Zuin A, Marulli G, Breda C et al. Pneumonectomy for lung cancer over the age of 75 years: is it worthwhile? Interact Cardiovasc Thorac Surg 2010; 10: 931-935.
50. Port JL, Mirza FM, Lee PC et al. Lobectomy in octogenarians with non-small cell lung cancer: ramifications of increasing life expectancy and the benefits of minimally invasive surgery. Ann Thorac Surg 2011; 92: 1951-1957.
51. Kiernan PD, Khandhar SJ, Fortes DL et al. Thoracic surgery in octogenarians: CVTSA/Inova Fairfax hospital experience, 1990 to 2009. Am Surg 2011; 77: 675-680.
52. Nakanishi R, Yamashita T, Oka S. Video-assisted thoracic surgery lobectomy for non-small cell lung cancer in patients with a Charlson comorbidity index score of two or more. J Thorac Oncol 2010; 5: 56-61.
53. Cattaneo SM, Park BJ, Wilton AS et al. Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg 2008; 85: 231-235.
54. Wisnivesky JP, Halm E, Bonomi M et al. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. Am J Respir Crit Care Med 2010; 181: 264-269.
55. Palma D, Senan S. Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. Curr Opin Oncol 2011; 23: 133-139.
56. Senthi S, Haasbeek CJ, Slotman BJ et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 2013; 106: 276-282.
57. Palma D, Visser O, Lagerwaard FJ et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010; 28: 5153-5159.
58. Palma D, Visser O, Lagerwaard FJ et al. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol 2011; 101: 240-244.
59. Shirvani SM, Jiang J, Chang JY et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012; 84: 1060-1070.
60. Cuffe S, Booth CM, Peng Y et al. Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. J Clin Oncol 2012; 30: 1813-1821.
61. Park S, Kim IR, Baek KK et al. Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. Ann Oncol 2013; 24: 1630-1639.
62. Rivera C, Jougon J, Dahan M et al. Are postoperative consequences of neoadjuvant chemotherapy for non-small cell lung cancer more severe in elderly patients? Lung Cancer 2012; 76: 216-221.
63. Wisnivesky JP, Halm EA, Bonomi M et al. Postoperative radiotherapy for elderly patients with stage III lung cancer. Cancer 2012; 118: 4478-4485.
64. Coate LE, Massey C, Hope A et al. Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol 2011; 6: 537-544.
65. Wanders R, Steevens J, Botterweck A et al. Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study. Eur J Cancer 2011; 47: 2691-2697.
66. Davidoff AJ, Gardner JF, Seal B et al. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol 2011; 6: 934-941.
67. Bayman N, Alam N, Faivre-Finn C. Radiotherapy for lung cancer in the elderly. Lung Cancer 2010; 68: 129-136.
68. Atagi S, Kawahara M, Yokoyama A et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012; 13: 671-678.
69. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer version 2.2013; http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. 2013 (June 2013, date last accessed)
70. Pallis AG, Wedding U, Lacombe D et al. Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know? Eur J Cancer 2010; 46: 1019-1025.
71. Gridelli C, Brodowicz T, Langer CJ et al. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2012; 13: 340-346.
72. Kawaguchi T, Tamiya A, Tamura A et al. Chemotherapy is beneficial for elderly patients with advanced non-small-cell lung cancer: analysis of patients aged 70-74, 75-79, and 80 or older in Japan. Clin Lung Cancer 2012; 13: 442-447.
73. Davidoff AJ, Tang M, Seal B et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2191-2197.
74. Zhu J, Sharma DB, Chen AB et al. Comparative effectiveness of three platinumdoublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Cancer 2013; 119: 2048-2060.
75. Chrischilles EA, Pendergast JF, Kahn KL et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 620-627.
76. Karampeazis A, Vamvakas L, Agelidou A et al. Docetaxel vs. vinorelbine in elderly patients with advanced non-small-cell lung cancer: a hellenic oncology research group randomized phase III study. Clin Lung Cancer 2011; 12: 155-160.
77. Quoix E, Zalcman G, Oster JP et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378: 1079-1088.
78. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25-32.
79. Newman AB, Yanez D, Harris T et al. Weight change in old age and its association with mortality. J Am Geriatr Soc 2001; 49: 1309-1318.
80. Kenis C, Bron D, Libert Y et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol 2013; 24: 1306-12.
81. Abe T, Yokoyama A, Takeda K et al. Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients ( pts) with advanced non-small cell lung cancer (NSCLC): an intergroup trial of JCOG0803/WJOG4307L. J Clin Oncol 2011; 29: abstr 7509.
82. Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30: 2055-2062.
83. Socinski MA, Langer CJ, Okamoto I et al. Safety and efficacy of weekly nab(R)- paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24: 314-321.
84. Spigel DR, Hainsworth JD, Shipley DL et al. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. J Thorac Oncol 2012; 7: 196-202.
85. Inal A, Kaplan MA, Kucukoner M et al. Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: a retrospective analysis of single institution. J BUON 2012; 17: 533-536.
86. Laskin J, Crino L, Felip E et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous nonsmall cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol 2012; 7: 203-211.
87. Wozniak AJ, Garst J, Jahanzeb M et al. Clinical outcomes (CO) for special populations of patients ( pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS). J Clin Oncol 2013; 28: abstr 7618.
88. Zhu J, Sharma DB, Gray SW et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 2012; 307: 1593-1601.
89. Maemondo M, Minegishi Y, Inoue A et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol 2012; 7: 1417-1422.
90. Inoue A, Kobayashi K, Usui K et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27: 1394-1400.
91. Asami K, Koizumi T, Hirai K et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer 2011; 12: 387-392.
92. Chen YM, Tsai CM, Fan WC et al. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol 2012; 7: 412-418.
93. Stinchcombe TE, Peterman AH, Lee CB et al. A randomized phase II trial of firstline treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2011; 6: 1569-1577.
94. Stinchcombe TE, Roder J, Peterman AH et al. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol 2013; 8: 443-451.
95. Riggs H, Jalal SI, Baghdadi TA et al. Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77. Clin Lung Cancer 2013; 14: 224-229.
96. Merimsky O, Cheng CK, Au JS et al. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer. Oncol Rep 2012; 28: 721-727.
97. Wu CH, Fan WC, Chen YM et al. Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. J Thorac Oncol 2010; 5: 376-379.
98. Repetto L, Piselli P, Raffaele M et al. Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGer study. Eur J Cancer 2009; 45: 374-383.
99. Girones R, Torregrosa D, Gomez-Codina J et al. Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians. Clin Transl Oncol 2012; 14: 183-189.
100. Surbone A, Kagawa-Singer M, Terret C et al. The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Oncol 2007; 18: 633-638.
101. Blinman P, Alam M, Duric V et al. Patients' preferences for chemotherapy in nonsmall- cell lung cancer: a systematic review. Lung Cancer 2010; 69: 141-147.
102. Oxnard GR, Fidias P, Muzikansky A et al. Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol 2007; 2: 1029-1035.
103. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.
104. Monfardini S, Balducci L. A comprehensive geriatric assessment (CGA) is necessary for the study and the management of cancer in the elderly. Eur J Cancer 1999; 35: 1771-1772.
105. Stuck AE, Siu AL, Wieland GD et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993; 342: 1032-1036.
106. Caillet P, Canoui-Poitrine F, Vouriot J et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011; 29: 3636-3642.
107. Girre V, Falcou MC, Gisselbrecht M et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? J Gerontol A Biol Sci Med Sci 2008; 63: 724-730.
108. Hurria A, Togawa K, Mohile SG et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29: 3457-3465.
109. Extermann M, Boler I, Reich RR et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118: 3377-3386.
110. Saliba D, Elliott M, Rubenstein LZ et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001; 49: 1691-1699.
111. Luciani A, Ascione G, Bertuzzi C et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 2010; 28: 2046-2050.
112. Bellera CA, Rainfray M, Mathoulin-Pelissier S et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012; 23: 2166-72.
113. Slaets JP. Vulnerability in the elderly: frailty. Med Clin North Am 2006; 90: 593-601.
114. Hamaker ME, Hamelinck VC, van Munster BC et al. Nonreferral of nursing home patients with suspected breast cancer. J Am Med Dir Assoc 2012; 13: 464-469.
115. Puts MT, Hardt J, Monette J et al. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst 2012; 104: 1134-1164.
116. Extermann M, Aapro M, Bernabei R et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241-252.